Ezlmica is an AI-native biotech company
advancing healthy longevity by addressing
aging, cancer, and disease with AI-driven
drug discovery and validation.
Predict safe repurposed drug combinations
from disease omics. Decompose, search,
and rank the most promising
therapeutic candidates.
Design peptide and mRNA vaccines
for cancer and aging targets using
AI-driven multi-omics analysis.
Track ex-vivo cancer response and
healthy-cell selectivity. Measure what
matters in controlled human
ex-vivo models.
From disease signals to promising therapies.
Guided by AI. Tested in human ex-vivo
models. A new standard in
AI-powered discovery.
Ezlmica integrates therapy design, vaccine
engineering, and ex-vivo validation to
accelerate healthy longevity research.
Our ambition is to build an AI-driven research platform that evolves alongside the science of longevity for decades to come -- from the therapies of today to the breakthroughs that will extend healthy human life to 150 years.
AI-driven discovery from disease signals to validated therapies.
Our approach: Rank, Test, Kill, Advance. From disease omics to promising therapies, guided by AI and validated in human ex-vivo models.